The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Sarfstein, Rive ^a   Bruchim, Ilan ^b   Fishman, Ami ^b   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CYCLIN D1; DALOTUZUMAB; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; COLONY FORMING UNIT E; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PHENOTYPIC VARIATION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; BIOLOGICAL MODEL; CELL CYCLE; CELL PROLIFERATION; ENDOMETRIUM TUMOR; METABOLISM; TUMOR CELL LINE; UTERUS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; UTERUS;

EID: 80052527908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024468     Document Type: Article

References (44)

1. Bokhman JV, (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17.
2. Lax SF, (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444: 213-223.
3. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, et al. (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54: 264-268.
4. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, et al. (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94: 642-646.
5. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al. (2004) Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 204: 569-577.
6. Nayak NR, Giudice LC, (2003) Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta 24: 281-296.
7. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, et al. (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17: 921-929.
8. Werner H, Bruchim I, (2009) The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71.
9. Werner H, (203) The molecular basis of IGF-I receptor gene expression in human cancer. In: LeRoith D, Zumkeller W, Baxter R, editors. Insulin-like growth factors Georgetown, Texas Landes Biosciences pp. 346-356.
10. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr, (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev 16: 143-163.
11. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B, (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-F126.
12. Gualberto A, Pollak M, (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021.
13. Siegel D, Hussein M, Belani C, Robert F, Galanis E, et al. (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2: 31.
14. Kelly WK, Richon VM, O'Connor OA, Curley T, MacGregor-Curtelli B, et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588.
15. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931.
16. Werner H, Bach MA, Stannard B, Roberts CT Jr, LeRoith D, (1992) Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol Endocrinol 6: 1545-1558.
17. Werner H, Rauscher FJ III, Sukhatme VP, Drummond IA, Roberts CT Jr, et al. (1994) Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 269: 12577-12582.
18. Brasaemle DL, Attie AD, (1988) Microelisa reader quantitation of fixed, stained, solubilized cells in microtitre dishes. Biotechniques 6: 418-419.
19. Quesnel B, Preudhomme C, Lepelley P, Hetuin D, Vanrumbeke M, et al. (1996) Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation. Br J Haematol 95: 291-298.
20. Honda H, Nakamoto T, Sakai R, Hirai H, (1999) p130(Cas), an assembling molecule of actin filaments, promotes cell movement, cell migration, and cell spreading in fibroblasts. Biochem Biophys Res Commun 262: 25-30.
21. Stimson L, La Thangue NB, (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280: 177-183.
22. Duriez PJ, Shah GM, (1997) Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349.
23. Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martinez Leal JF, et al. (2010) Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 95: 613-621.
24. Marks PA, Breslow R, (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
25. Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H, (2006) Transcriptional regulation of the insulin-like growth factor-1 receptor in breast cancer. Mol Cell Endocrinol 252: 241-246.
26. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D, (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23: 786-794.
27. Hata H, Kuramoto H, (1992) Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J Steroid Biochem Mol Biol 42: 201-210.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC, (1991) p53 mutations in human cancers. Science 253: 49-53.
29. Reynolds RK, Hu C, Baker VV, (1998) Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. Gynecol Oncol 70: 202-209.
30. Idrees MT, Schlosshauer P, Li G, Burstein DE, (2006) GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. Histopathology 49: 75-81.
31. Kang-Park S, Lee YI, Lee YI, (2003) PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 545: 203-208.
32. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545.
33. Rutanen EM, (1998) Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12: 399-406.
34. Esteller M, (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16: R50-59.
35. Risinger JI, Maxwell GL, Berchuck A, Barrett JC, (2003) Promoter hypermethylation as an epigenetic component in Type I and II endometrial cancers. Ann NY Acad Sci 983: 208-212.
36. Fulda S, Debatin KM, (2005) HDAC inhibitors: double edge sword for TRAIL cancer therapy? Cancer Biol Ther 4: 1113-1115.
37. Ashkenazi A, (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430.
38. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, et al. (2008) Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 14: 2543-2550.
39. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, et al. (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589.
40. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, et al. (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275: 20436-20443.
41. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, et al. (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21: 6236-6245.
42. Gridelli C, Rossi A, Maione P, (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 68: 29-36.
43. Richon VM, Sandhoff TW, Rifkind RA, Marks PA, (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019.
44. Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, et al. (2006) Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb 13: 183-191.